The device landscape,
mapped and measured.
Technical specifications, clinical trial outcomes, and regulatory precedents for the neurotechnology industry. Stop guessing on power budgets and FDA predicates.
Primary Modalities
View all modalities →Deep Brain Stimulation (DBS)
Established interventions for movement disorders (Parkinson's, Essential Tremor) and emerging indications for psychiatric conditions.
Spinal Cord Stimulation (SCS)
Dominant modality for chronic intractable pain. Evolving waveforms (tonic, burst, high-frequency) and closed-loop systems.
Brain-Computer Interfaces (BCI)
High-density recording and stimulation for motor decoding, sensory restoration, and communication in severe paralysis.
The shift to closed-loop.
Open-loop continuous stimulation is rapidly becoming obsolete. Next-generation devices require significant edge compute for real-time biomarker extraction and stimulation parameter adjustment.
This demands new power architectures, custom ASICs, and entirely new paradigms for FDA software-as-a-medical-device (SaMD) clearance.
Read the technical guide on closed-loop architectures →Engineering Calculators
Stop relying on messy spreadsheets. Use our verified calculators for common neurotech engineering challenges, complete with references to underlying physics and regulatory limits.
Charge Density & Injectable Charge Limit
Calculate Shannon equations to ensure stimulation stays within safe electrochemical limits (k=1.5).
Use Tool →Implant Power Budget Estimator
Model quiescent vs. active state power consumption for telemetry, stimulation, and sensing.
Use Tool →Thermal Noise & SNR
Estimate thermal (Johnson-Nyquist) noise based on electrode impedance and amplifier bandwidth.
Use Tool →Recording Data Rate
Calculate raw telemetry payload requirements based on channel count, sampling rate, and ADC resolution.
Use Tool →Recent Clinical Outcomes
| Study / Device | Indication | N | Primary Endpoint Outcome |
|---|---|---|---|
| COMMAND Trial (Synchron Stentrode) | Severe Paralysis (ALS/SCI) | 6 | No device-related serious adverse events at 12m. Achieved digital motor endpoints. |
| RNS System Long-Term Outcome | Drug-Resistant Epilepsy | 256 | Median seizure frequency reduction of 75% at 9 years. |
| EVALUATE RCT (Saluda Evoke) | Chronic Back & Leg Pain | 134 | 83% of ECAP closed-loop patients achieved ≥50% pain reduction at 24m vs 61% open-loop. |
Navigating the FDA
Neuromodulation devices face intense scrutiny. Understanding the predicate landscape for 510(k) or preparing for a PMA via the Breakthrough Devices Program is critical.
Regulatory DatabaseInvestigational Device Exemption (IDE)
Required for significant risk devices before beginning U.S. human trials. Requires extensive bench and animal data.
Read the IDE GuideBreakthrough Device Program
For devices treating life-threatening or irreversibly debilitating conditions. Provides priority review.
Read the BDP GuideCommon Engineering Pitfalls
Ignoring tissue encapsulation in impedance models.
Benchtop saline testing dramatically underestimates chronic impedance. Within weeks of implant, foreign body response creates a fibrous capsule around the array, increasing impedance by 2-5x. If your compliance voltage maxes out at 1kΩ, you will lose stimulation efficacy in vivo. Read our tissue modeling guide.
Underestimating data telemetry constraints.
A 1024-channel array sampling at 30kHz produces ~490 Mbps of raw data. This cannot be wirelessly transmitted through tissue using standard BLE. You must implement aggressive on-device feature extraction (e.g., threshold crossing, LFP bandpower) to reduce the data rate before telemetry.
Failing to balance charge in biphasic pulses.
Even 1% charge imbalance over millions of cycles will lead to irreversible faradaic reactions, electrode dissolution, and tissue necrosis. Active charge balancing circuits and blocking capacitors are mandatory, not optional.
Track the landscape.
Get notified when we add new clinical trial outcomes, FDA clearances, and engineering tools to the database. No fluff, just data.
Major Market Players
Percept PC
DBS with BrainSense technology for chronic LFP recording.
Vercise Genus
Directional DBS with MICC (Multiple Independent Current Control).
Proclaim XR
SCS utilizing BurstDR stimulation at low doses.
RNS System
Closed-loop responsive neurostimulation for epilepsy.
Deconstructing the Implant
Modern neuromodulation devices consist of three discrete subsystems, each carrying distinct regulatory and engineering risks.
-
1
IPG (Implantable Pulse Generator)
Houses the battery (primary or secondary), ASIC, and telemetry coils. Usually implanted in the subclavicular or gluteal region.
-
2
Extension Leads
Subcutaneous wiring bridging the IPG to the neural target. A common site for mechanical fracture failure modes.
-
3
Electrode Array
The tissue interface (e.g. Platinum-Iridium contacts). Governed by strict electrochemical limits like the Shannon charge density equation.
Material Constraints
Choosing the right biomaterials dictates the chronicity of your device. Accelerated aging tests (e.g., at 85°C) are required for FDA submission.
Read the Materials Guide →Encapsulation (Hermeticity)
Titanium cans welded with Nd:YAG lasers achieve moisture ingress rates acceptable for decades of implantation. Polymer encapsulants (LCP, Parylene-C) often fail chronic tests.
Insulation
Polyurethane and Silicone remain industry standards for lead bodies. Polyimide is used for flexible thin-film arrays, but suffers from long-term hydrolysis.
Electrode Coatings
Sputtered Iridium Oxide (SIROF) or PEDOT:PSS are utilized to dramatically lower 1kHz impedance and increase the safe charge injection limit relative to bare PtIr.